Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items ...

INmune Bio Inc. (NASDAQ: INMB) (the 'Company”), a clinical-stage inflammation and immunology company, today announced that it ...

Mesoblast Limited (NASDAQ:MESO) is one of the 7 Best ASX Stocks to Buy Now. The company announced that it received 7 years of ...

NeuroScientific Biopharmaceuticals has acquired unlisted Perth-based Isopogen for $5.1 million, gaining control of the ...

The complex tumor microenvironment (TME) in osteosarcoma is emerging as a critical factor in disease progression and ...

The complex tumor microenvironment (TME) in osteosarcoma is emerging as a critical factor in disease progression and treatment resistance. Recent ...